Latest News
-
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of Eylea (aflibercept…
Regeneron announced that the FDA has accepted for review the company's supplemental Biologics License Application for a 12-week dosing i…
from EyewireToday.com
-
Second Sight Announces Market Entry into Iran with First Two Implants of Argus II Retinal …
Second Sight Medical Products announced market entry into Iran, implanting the first two patients with the company’s Argus II Retinal …
from EyewireToday.com
-
Vortex Surgical Launches Innovative Convenience Kits
Vortex Surgical announced the release of the Vortex Surgical Convenience Kit. Launched during the annual meeting of the American Academy of …
from EyewireToday.com
-
Novartis: Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Seconda…
Novartis announced further positive results from two phase 3 studies of brolucizumab versus aflibercept (Eylea). Results showed noninferiori…
from EyewireToday.com
-
Genentech Makes Statement Following Release of Novartis' Brolucizumab Data
At the American Academy of Ophthalmology meeting in New Orleans, Novartis announced positive results from two phase 3 studies (HAWK and HARR…
from EyewireToday.com
-
Three-year Follow-up Phase 3 Data Provide Additional Information on Luxturna in Patients w…
Spark Therapeutics announced new 3-year follow-up data from the continuing phase 3 trial of Luxturna (voretigene neparvovec), an investigati…
from EyewireToday.com
-
OD-OS Announces New Framework for Remote Planning of Navigated Retinal Laser Treatments
OD-OS announced the upcoming release of NaviGATE - a new framework for remote planning of retinal treatments with the Navilas 577s navigated…
from EyewireToday.com
-
Novartis Pivotal Brolucizumab (RTH258) Data to be Presented at AAO
Novartis will be presenting more detailed results from its phase 3 studies (HAWK and HARRIER) of brolucizumab (RTH258) vs. aflibercept for t…
from EyewireToday.com
-
Allergan Receives Approval for Ozurdex in China for the Treatment of Retinal Vein Occlusio…
Allergan announced that it has received an imported drugs license from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (de…
from EyewireToday.com
-
Lin BioScience Receives FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt …
Lin BioScience announced that the FDA has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Sta…
from EyewireToday.com
-
Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial …
Clearside Biomedical announced completion of patient enrollment in the phase 2 clinical trial (TYBEE) of CLS-TA, Clearside’s proprieta…
from EyewireToday.com
-
Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System f…
Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomi…
from EyewireToday.com
-
ThromboGenics Announces Publication in Experimental Eye Research of Preclinical Data Suppo…
ThromboGenics NV announced that preclinical data on its THR-317 have been published in Experimental Eye Research. ThromboGenics’ precl…
from EyewireToday.com
-
PanOptica Secures Funding to Advance Clinical Development of PAN-9080 Topical Anti-VEGF Ey…
PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule an…
from EyewireToday.com
